Carl E Ruby
Overview
Explore the profile of Carl E Ruby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
970
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kaufman H, Ruby C, Hughes T, Slingluff Jr C
J Immunother Cancer
. 2014 Jun;
2:11.
PMID: 24971166
In 2012, it was estimated that 9180 people in the United States would die from melanoma and that more than 76,000 new cases would be diagnosed. Surgical resection is effective...
12.
Farazi M, Cohn Z, Nguyen J, Weinberg A, Ruby C
J Leukoc Biol
. 2014 Apr;
96(2):245-54.
PMID: 24714553
Decline in CD4 T cell immune responses is associated with aging. Although a number of immunological defects have been identified in elderly mice (>18 months old), a key early-onset immune...
13.
Farazi M, Nguyen J, Goldufsky J, Linnane S, Lukaesko L, Weinberg A, et al.
Cancer Immunol Immunother
. 2014 Apr;
63(6):615-26.
PMID: 24682539
Immune responses wane during aging, posing challenges to the potential effectiveness of cancer immunotherapies. We previously demonstrated that in the context of a promising immunotherapeutic, OX40 agonist (αOX40), older animals...
14.
Vasilevsky N, Ruby C, Hurlin P, Weinberg A
Eur J Immunol
. 2011 Mar;
41(4):1024-34.
PMID: 21400495
OX40 engagement on activated T cells leads to increased proliferation, expansion and survival of Ag-specific T cells. Direct ex vivo examination of Ag-stimulated murine T cells show that the Myc...
15.
Jensen S, Maston L, Gough M, Ruby C, Redmond W, Crittenden M, et al.
Semin Oncol
. 2010 Nov;
37(5):524-32.
PMID: 21074068
The existence of tumor-specific T cells, as well as their ability to be primed in cancer patients, confirms that the immune response can be deployed to combat cancer. However, there...
16.
Ruby C, Yates M, Hirschhorn-Cymerman D, Chlebeck P, Wolchok J, Houghton A, et al.
J Immunol
. 2009 Sep;
183(8):4853-7.
PMID: 19786544
We report that OX40 stimulation drives all lineages of CD4 T cell development, including regulatory T cells (Tregs), and the plasticity of the response is dependant on local cytokines. In...
17.
Redmond W, Ruby C, Weinberg A
Crit Rev Immunol
. 2009 Jun;
29(3):187-201.
PMID: 19538134
The extent of T-cell activation, proliferation, and survival that follows T-cell receptor (TCR) ligation is controlled by several factors, including the strength of TCR stimulation, the availability of prosurvival cytokines,...
18.
Ruby C, Weinberg A
Cancer Immunol Immunother
. 2009 Mar;
58(12):1941-7.
PMID: 19288101
Agents that enhance T cell co-stimulatory signaling have emerged as promising cancer immunotherapies. Our laboratory has been evaluating the TNF receptor co-stimulatory molecule, OX40, which has the capacity to augment...
19.
Ruby C, Weinberg A
J Immunol
. 2009 Jan;
182(3):1481-9.
PMID: 19155495
OX40 agonists have potent immunotherapeutic effects against a variety of murine tumors, yet it is unclear the role that age-related immune senescence plays on their efficacy. We found that middle-aged...
20.
Ruby C, Funatake C, Kerkvliet N
J Immunotoxicol
. 2008 Oct;
1(3):159-66.
PMID: 18958649
2,3,7,8 Tetrachlorodibenzo-p-dioxin (TCDD) suppresses adaptive immune responses and modulates the function of numerous cells involved in these responses. Our laboratory has shown that dendritic cells (DCs), which are important for...